(Q38119752)

29 August 2017

title

Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study (English)

1 reference

29 August 2017

1 reference

Gina Ogilvie

7

0 references

Eduardo L. Franco

Eduardo L Franco

5

0 references

Marie-Claude Boily

Marie-Claude Boily

9

0 references

Shelley Deeks

8

Shelley L Deeks

1 reference

29 August 2017

3

Mélanie Drolet

1 reference

29 August 2017

4

Nicolas Van de Velde

1 reference

29 August 2017

Jean-François Laprise

2

Jean-François Laprise

1 reference

29 August 2017

6

Erich V Kliewer

1 reference

29 August 2017

Marc Brisson

1

1 reference

29 August 2017

language of work or name

English

0 references

publication date

3 July 2013

1 reference

29 August 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

29 August 2017

volume

31

1 reference

29 August 2017

issue

37

1 reference

29 August 2017

page(s)

3863-3871

1 reference

Classification of papillomaviruses

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Adult respiratory papillomatosis: human papillomavirus type and viral coinfections as predictors of prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

A review of human carcinogens--Part B: biological agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Systematic review of human papillomavirus prevalence in invasive penile cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Epidemiologic classification of human papillomavirus types associated with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

An analytical framework for immunization programs in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Economic evaluation of human papillomavirus vaccination in developed countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Modeling cervical cancer prevention in developed countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Cost-effectiveness of different human papillomavirus vaccines in Singapore

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Population-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Model–Based Analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

The psychosocial impact of an abnormal cervical smear result.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

The impact of anogenital warts on health-related quality of life: a 6-month prospective study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Cervical cancer in Canada: changing patterns in incidence and mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Toward consistency in cost-utility analyses: using national measures to create condition-specific values

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Patients' perceived health status following primary surgery for oral and oropharyngeal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Epidemiology and costs associated with genital warts in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Costs of colposcopy services and their impact on the incidence and mortality rate of cervical cancer in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

The economic burden of noncervical human papillomavirus disease in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Funding of drugs: do vaccines warrant a different approach?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

On discounting of health gains from human papillomavirus vaccination: effects of different approaches.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Economic evaluation of human papillomavirus vaccination in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Head and neck cancer in Canada: trends 1992 to 2007.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Impact of the HIV epidemic on the incidence rates of anal cancer in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Human papillomavirus genotype distribution in external acuminata condylomata: a Large French National Study (EDiTH IV).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

Time for change? An economic evaluation of integrated cervical screening and HPV immunization programs in Canada.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.064

10.1016/J.VACCINE.2013.06.064

7 January 2021

Identifiers

DOI

1 reference

release_dszvrrdmcja6rgty5dzp5qsai4

29 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dszvrrdmcja6rgty5dzp5qsai4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference